{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:03:42Z","timestamp":1791277422111,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ijbiomac.2024.132058","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T01:23:59Z","timestamp":1714699439000},"page":"132058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"P2","title":["ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy"],"prefix":"10.1016","volume":"269","author":[{"given":"Dianlong","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjia","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2024.132058_bb0005","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0010","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","article-title":"Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity","volume":"56","author":"Park","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0015","article-title":"Immunotherapy: reshape the tumor immune microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0020","first-page":"3312","article-title":"Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy","volume":"12","author":"Wang","year":"2020","journal-title":"Aging (Albany N. Y.)."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101305","article-title":"Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor","volume":"42","author":"Ruffo","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0030","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1084\/jem.20182395","article-title":"Development of immune checkpoint therapy for cancer","volume":"216","author":"Fritz","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0035","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.7150\/ijbs.60782","article-title":"CD47\/SIRP\u03b1 pathway mediates cancer immune escape and immunotherapy","volume":"17","author":"Jia","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0040","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1172\/JCI94586","article-title":"Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression","volume":"128","author":"Hossain","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0045","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","article-title":"Programmed death ligand 1 signals in cancer cells","volume":"22","author":"Kornepati","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0050","doi-asserted-by":"crossref","first-page":"6951","DOI":"10.1038\/s41467-022-34346-x","article-title":"Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation","volume":"13","author":"Shi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0055","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/2159-8290.CD-21-1357","article-title":"The spatial landscape of progression and immunoediting in primary melanoma at single-cell resolution","volume":"12","author":"Nirmal","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0060","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun. (Lond)"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032747","article-title":"Research trends and most influential clinical studies on anti-PD1\/PDL1 immunotherapy for cancers: a bibliometric analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0075","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","article-title":"De-novo and acquired resistance to immune checkpoint targeting","volume":"18","author":"Syn","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0080","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.3390\/ijms21113769","article-title":"Affibody-binding ligands","volume":"21","author":"Barozzi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0085","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2019.02022","article-title":"PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition","volume":"10","author":"Wu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0090","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/cancers11020232","article-title":"PDL-1 antibody drug conjugate for selective chemo-guided immune modulation of cancer","volume":"11","author":"Sau","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0095","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202304328","article-title":"A hybrid nanoadjuvant simultaneously depresses PD-L1\/TGF-\u03b21 and activates cGAS-STING pathway to overcome radio-immunotherapy resistance","volume":"36","author":"Yi","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0105","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1021\/acsnano.3c10117","article-title":"Mitochondrial disruption nanosystem simultaneously depressed programmed death ligand-1 and transforming growth factor-\u03b2 to overcome photodynamic immunotherapy resistance","volume":"18","author":"Jiang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127911","article-title":"Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: a review","volume":"254","author":"Zhou","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0115","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.febslet.2010.04.014","article-title":"Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications","volume":"584","author":"L\u00f6fblom","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121746","article-title":"Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors","volume":"620","author":"Jia","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119541","article-title":"Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models","volume":"586","author":"Jia","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0130","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1021\/acschembio.2c00218","article-title":"Directed evolution of PD-L1-targeted affibodies by mRNA display","volume":"17","author":"Grindel","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.754436","article-title":"Kickstarting immunity in cold tumours: localised tumour therapy combinations with immune checkpoint blockade","volume":"12","author":"Appleton","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0140","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","article-title":"Turning cold tumors hot: from molecular mechanisms to clinical applications","volume":"43","author":"Zhang","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0145","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0150","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0155","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120964","article-title":"Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy","volume":"275","author":"Cheng","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0165","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1039\/C8CS00618K","article-title":"Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer","volume":"48","author":"Liu","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0170","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.2147\/IJN.S388996","article-title":"Combined photodynamic and photothermal therapy and immunotherapy for cancer treatment: a review","volume":"17","author":"Kong","year":"2022","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121609","article-title":"Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors","volume":"617","author":"Liu","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0180","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.7150\/thno.80091","article-title":"Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy","volume":"13","author":"Yin","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0185","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.actbio.2021.09.052","article-title":"A combination strategy based on an Au nanorod\/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle","volume":"136","author":"Feng","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0190","doi-asserted-by":"crossref","first-page":"30145","DOI":"10.1021\/acsami.0c07013","article-title":"Photothermal fenton nanocatalysts for synergetic cancer therapy in the second near-infrared window","volume":"12","author":"Sun","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0195","article-title":"NIR-triggered phototherapy and immunotherapy via an antigen-capturing nanoplatform for metastatic cancer treatment","volume":"6","author":"Wang","year":"2019","journal-title":"Adv. Sci. (Weinh)."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0200","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12951-021-00932-2","article-title":"Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer","volume":"19","author":"Zhao","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0205","doi-asserted-by":"crossref","first-page":"13304","DOI":"10.1021\/acsnano.9b06467","article-title":"Nanoscale covalent organic framework for combinatorial antitumor photodynamic and photothermal therapy","volume":"13","author":"Guan","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0210","doi-asserted-by":"crossref","first-page":"7789","DOI":"10.1245\/s10434-023-13953-y","article-title":"Identification of pediatric tumors intraoperatively using indocyanine green (ICG)","volume":"30","author":"Pio","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0215","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1021\/acs.bioconjchem.9b00239","article-title":"Affibody-indocyanine green based contrast agent for photoacoustic and fluorescence molecular imaging of B7-H3 expression in breast cancer","volume":"30","author":"Bam","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0220","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/jso.26190","article-title":"Dual-agent fluorescent labeling of soft-tissue sarcomas improves the contrast based upon targeting both interstitial and cellular components of the tumor milieu","volume":"122","author":"Sardar","year":"2020","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0225","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1021\/acs.molpharmaceut.2c00708","article-title":"ICG-dimeric Her2-specific affibody conjugates for tumor imaging and photothermal therapy for Her2-positive tumors","volume":"20","author":"Jia","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0230","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12951-021-00885-6","article-title":"Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy","volume":"19","author":"Wang","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0235","doi-asserted-by":"crossref","first-page":"747","DOI":"10.7150\/thno.65828","article-title":"Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells","volume":"12","author":"Tu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0240","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002970","article-title":"Synergy between Toxoplasma gondii type I \u0394GRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors","volume":"9","author":"Zhu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112098","article-title":"Preparation of ROS active and photothermal responsive hydroxyapatite nanoplatforms for anticancer therapy","volume":"125","author":"Chang","year":"2021","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113935","article-title":"A novel ICG-labeled cyclic TMTP1 peptide dimer for sensitive tumor imaging and enhanced photothermal therapy in vivo","volume":"227","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0255","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4103\/jcrt.jcrt_88_23","article-title":"An overview of current advances of PD-L1 targeting immuno-imaging in cancers","volume":"19","author":"Chen","year":"2023","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0260","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2016.03.004","article-title":"Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL","volume":"228","author":"Li","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0265","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.7150\/thno.23880","article-title":"Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects","volume":"8","author":"Yang","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0270","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jconrel.2021.11.003","article-title":"A versatile platform for the tumor-targeted delivery of immune checkpoint-blocking immunoglobin G","volume":"340","author":"Fan","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2024.132058_bb0275","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024028630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024028630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T11:31:38Z","timestamp":1719919898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813024028630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":55,"alternative-id":["S0141813024028630"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.132058","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.132058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"132058"}}